Recent Developments in RSV and Vaccine Recommendations
TL;DR Summary
Moderna's stock rose after CDC recommended its RSV vaccine for at-risk adults aged 50-59, aligning with previous advisory panel recommendations, despite earlier uncertainties following Robert F. Kennedy Jr.'s decision to replace the advisory panel. This expands Moderna's market for the vaccine, which competes with Pfizer and GSK, and signals potential future growth despite past sales misses.
- Robert F. Kennedy Jr. Just Did The Unexpected. He Helped Moderna. Investor's Business Daily
- CDC accepts RSV recommendations made by former vaccine panel USA Today
- ACIP Recommends Use of Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Younger than 8 Months of Age Born During or Entering Their First RSV Season Merck.com
- RFK Jr’s vaccine panel recommends new RSV treatment for infants The Guardian
- RSV vaccine access expanded to some people in their 50s, according to CDC website Newsday
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
1 min
vs 2 min read
Condensed
84%
341 → 56 words
Want the full story? Read the original article
Read on Investor's Business Daily